Searchable abstracts of presentations at key conferences in endocrinology

ea0016p551 | Obesity | ECE2008

Prevalence of non alcoholic steatohepatitis in diabetic patients with morbid obesity

Segovia Raquel , Camara Rosa , Del Olmo Maribel , Ponce Jose , Navas Soledad , Argente Maria , Pinon Francisco

Non alcoholic steatohepatitis (EHNA) is diagnosed by hepatic biopsy. Its etiology is uncertain but obesity is present in 69–100% of all cases and type 2 diabetes mellitus (DM) in about 34–75%.Objectives: To study the prevalence of EHNA in morbidly obese patients and determine if there is a difference between the prevalence in patients with and without carbohydrate metabolism disorders.Patients and methods: Prospective stu...

ea0056gp138 | Neuroendocrinology | ECE2018

Hypermethylation of tumour suppressor genes in pituitary adenomas: contribution to oncogenesis and tumour behaviour

Garcia-Martinez Araceli , Sottile Johana , Fajardo Carmen , Camara Rosa , Lamas Cristina , Pico Antonio

Introduction: Epigenetic and genetic alterations contribute to cancer initiation and progression. These alterations may be playing a determinant role in the development of pituitary adenomas (PAs). One of these epigenetic processes is the DNA methylation and, specifically, methylation of Tumour Suppressor Genes (TSG). TSG are key elements that allow the maintenance of cellular homeostasis. Due to epigenetic changes are reversible, a better understanding of the underlying epige...

ea0056gp195 | Pituitary Basic | ECE2018

Filamin A (FLNA) phosphorylation inhibits SSTR2 signal transduction in GH-secreting pituitary tumor cells

Peverelli Erika , Catalano Rosa , Giardino Elena , Mangili Federica , Treppiedi Donatella , Arosio Maura , Spada Anna , Mantovani Giovanna

Despite the increasing evidence on the relevance of the actin binding protein filamin A (FLNA) in determining an efficient intracellular response to somatostatin analogs (SSA) in pituitary tumors, there is a gap in the knowledge on the mechanisms regulating FLNA itself. FLNA is phosphorylated by PKA on Ser2152 located in a FLNA region crucial for SST2 or partner proteins binding. Although cAMP/PKA pathway plays a crucial role in GH-secreting tumors pathogenesis, the...

ea0056p75 | Adrenal medulla | ECE2018

Malignant pheochromocytoma discovered upon consultation for painful erections

Garcia-Garcia-Doncel Lourdes , Marquez-Pardo Rosa , Cayon-Blanco Manuel , Lopez-Velasco Rosario , Baena-Nieto Gloria

Introduction: Pheochromocytomas (PCCs) and paragangliomas (PGL) are rare but unique tumors. Only 10% of PCCs are malignant, defined by metastases. Metastases can be seen at diagnosis of the primary tumor or develop even 20 years later. Approximately half of patients with metastatic PCC/PGL have inherited SDHB mutations.Case report: A 45-year-old man was referred to Urology for curvature of the penis and painful erections. Among his medical background hig...

ea0056p219 | Calcium & Vitamin D metabolism | ECE2018

PTH threshold for hyperparathyroidism diagnosis in vitamin D deficiency

Baena-Nieto Gloria , Marquez-Pardo Rosa , Cayon-Blanco Manuel , Garcia-Garcia-Doncel Lourdes

Introduction: Vitamin D insufficiency is very common among Spanish adults. It is well established there is an inverse relationship between vitamin D and PTH levels. The diagnostic approach of an increased serum PTH concentration in a normocalcemic normophosphatemic patient is frequent in routine practice and the deficiency of vitamin D is the major cause of secondary hyperparathyroidism (SHPT). The aims of this study were to evaluate the prevalence of SHPT in a cohort of normo...

ea0056p484 | Diabetes therapy | ECE2018

Dapagliflozin after liraglutide in patients with type 2 diabetes

Moreno-Moreno Paloma , Munoz-Jimenez Concepcion , Alhambra-Exposito Maria Rosa , Galvez-Moreno Maria Angeles

Objective: To evaluate the efficacy of dapagliflozin for glycemic control and progression of weight loss after stabilization with liraglutide 1.8 mg.Patients and methods: Descriptive study: patients with tipo 2 diabetes (DM-2) in treatment with metformin and liraglutide 1.8 mg, optimal metabolic control, which after stabilization in weight loss, liraglutide is suspended and dapagliflozin is added. Variables analyzed baseline and at 6 months after treatme...

ea0056p485 | Diabetes therapy | ECE2018

Canagliflozin after liraglutide in patients with type 2 diabetes

Moreno-Moreno Paloma , Alhambra-Exposito Maria Rosa , Munoz-Jimenez Concepcion , Galvez-Moreno Maria Angeles

Objective: To evaluate the efficacy of canagliflozin 100 mg for glycemic control and progression of weight loss after stabilization with liraglutide 1.8 mg.Patients and methods: Descriptive study: patients with type 2 diabetes (DM-2) in treatment with metformin and liraglutide 1.8 mg, optimal metabolic control, which after stabilization in weight loss, liraglutide is suspended and canagliflozin 100 mg is added. Variables analyzed baseline and at 6 months...

ea0056p486 | Diabetes therapy | ECE2018

Inhibitors SGLT2 after liraglutide in patients with type 2 diabetes

Moreno-Moreno Paloma , Munoz-Jimenez Concepcion , Alhambra-Exposito Maria Rosa , Galvez-Moreno Maria Angeles

Objetive: The change of treatment of liraglutide 1.8 mg to dapagliflozin or canaglifonzin 100 mg in patients with optimal glycemic control and stabilization weight loss, achieves progression in weight loss and improves the metabolic control of the patient with tipo 2 diabetes (DM-2). Our objective is to evaluate if there are differences in metabolic control and progression of weight loss in patients treated with canagliflozin 100 mg or dapagliflozin.Pati...

ea0056p555 | Obesity | ECE2018

Are there differences in cardiovascular risk between metabolically healthy and sick obese?

Rosa Alhambra Exposito Maria , Munoz Jimenez Concepcion , Calanas Continente Alfonso , Jose Molina Puerta Maria

Introduction: Obesity is a major health problem and a risk factor for the development of other diseases. However, there are morbid obese subjects of long evolution that can be considered metabolically healthy obese, whose existence is in doubt for many clinicians.Objetive: To analyze if there are differences in cardiovascular risk between metabolically healthy (MHO) and sick obese (MSO), matched by age, sex and body mass index (BMI).<p class="abstext...

ea0056p702 | Clinical case reports - Pituitary/Adrenal | ECE2018

Cyclic Cushing’s syndrome: a difficult diagnosis

Marquez-Pardo Rosa , Garcia-Garcia-Doncel Lourdes , Baena-Nieto Maria-Gloria

Introduction: Cyclic Cushing’s syndrome (CS) is a rare disorder characterized by repeated episodes of cortisol excess interspersed by periods of normal cortisol secretion. These phases may range from days to years. The diagnosis is a difficult challenge.Case report: We present a case of 56-year-old women with hyperglycemia, hypertension, central obesity, edema, bruising, fatigue and emotional lability for several years. Laboratory tests: glucose 141...